Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Malignant Neoplasm
100%
Emergency Department
93%
Immune Checkpoint Inhibitor
37%
Infection
29%
Procalcitonin
28%
Neutropenia
22%
COVID-19
21%
Febrile Neutropenia
21%
Adverse Effect
20%
Intensive Care Unit
20%
Immunity
16%
Immune-Related Adverse Events
16%
Triage
15%
Central Venous Catheter
14%
Antimicrobial Therapy
13%
Treatment Duration
13%
Venous Thromboembolism
12%
Hematologic Malignancy
12%
Bloodstream Infection
11%
Antibiotics
11%
Cancer Therapy
11%
Advanced Cancer
10%
Lactic Acid
10%
Adverse Event
10%
Hospital Mortality
10%
Chimeric Antigen Receptor T-Cell
10%
Catheter Removal
9%
Catheter Infection
9%
Diabetic Ketoacidosis
8%
Myocarditis
8%
Oncology
8%
Brain Metastasis
8%
Cohort Effect
7%
Supportive Care
7%
Pembrolizumab
7%
Recurrent Disease
6%
Chimeric Antigen Receptor T-Cell Immunotherapy
6%
Genome Wide Association Study
6%
Oxygen Saturation
6%
Infusion Therapy
6%
Blood Culture
6%
Neuropathic Pain
6%
Phlebothrombosis
6%
Head and Neck Cancer
6%
Advance Care Planning
6%
Ceftolozane
6%
Catheter Thrombosis
6%
End of Life Care
6%
Neuropathy
6%
Postcovid Syndrome
6%
Keyphrases
Cancer Patients
61%
Emergency Department
42%
In Cancer
37%
Comprehensive Cancer Center
27%
Patients with Cancer
27%
Procalcitonin
21%
Neutropenia
17%
Antimicrobial Therapy
15%
Emergency Department Observation Unit
13%
Documented Infection
13%
Duration of Therapy
13%
Hospital Mortality
13%
Bloodstream Infection
13%
Immune Checkpoint Inhibitors
13%
Invasive Aspergillosis
13%
COVID-19
11%
Risk Factors
10%
Hematological Malignancies
10%
Emergency Department Visits
9%
Chimeric Antigen Receptor T Cells (CAR-T)
9%
30-day Mortality
9%
Poor Outcome
8%
Presenting Symptoms
8%
Pembrolizumab
8%
Patients with Advanced Cancer
8%
Intensive Care Unit Admission
8%
Docetaxel Chemotherapy
6%
Chimeric Antigen Receptor T-cell Therapy
6%
Survivorship
6%
Cell Infusion
6%
In-hospital Mortality
6%
Treatment Modalities
6%
Immune-related Adverse Effects
6%
Adverse Events Profile
6%
Risk Treatment
6%
Anticancer Immune Response
6%
International multicenter Study
6%
Immune Checkpoint Therapy
6%
Checkpoint Inhibitor Immunotherapy
6%
MR-proADM
6%
Retrospective Cohort Study
6%
Central Venous Catheter
6%
Bupropion
6%
Gut Microbiome
6%
Emergency Severity Index
6%
Observation Medicine
6%
Sepsis Biomarkers
6%
Cancer Pain
6%
Smoking Abstinence
6%
Emergency Department Use
6%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
75%
Procalcitonin
27%
Infection
23%
Febrile Neutropenia
21%
Immune Checkpoint Inhibitor
20%
Hematologic Malignancy
17%
Adverse Event
17%
Neutropenia
16%
Chemotherapy
14%
Antibiotics
13%
Pembrolizumab
13%
Pyrrole
13%
Mould
13%
Invasive Aspergillosis
13%
Antimicrobial Therapy
8%
Biological Marker
8%
Immunotherapy
8%
Lung Cancer
7%
Bloodstream Infection
7%
Cohort Study
7%
Myositis
6%
Syndrome
6%
Relebactam
6%
Aspergillus terreus
6%
Myasthenia gravis
6%
Sustained Release
6%
Ritonavir
6%
Proadrenomedullin
6%
Bupropion
6%
Neuropathic Pain
6%
Imipenem
6%
Cilastatin
6%
Myocarditis
6%
Tazobactam
6%
Neuropathy
6%
Docetaxel
6%
Sepsis
6%
Chimeric Antigen Receptor
6%
Ceftolozane
6%
Head and Neck Cancer
6%
Varenicline
6%
Nirmatrelvir
6%
Molnupiravir
6%
Advanced Cancer
6%
Diabetic Ketoacidosis
6%
Prostate Cancer
6%
Dyspnea
6%
Delirium
5%
